New York reports first locally acquired chikungunya case in U.S. since 2019
Source: SeekingAlpha
2025-10-15 13:46:59 ET
More on Valneva, Bavarian Nordic, etc.
- Valneva Outlook: Safety Blow To Ixchiq And Valuation Concerns
- Bavarian Nordic A/S 2025 Q2 - Results - Earnings Call Presentation
- Bavarian Nordic A/S (BVNKF) Q2 2025 Earnings Call Transcript
- Valneva lowers 2025 financial outlook due to loss of Ixchiq vaccine marketing
- Valneva suspended from marketing chikungunya shot in U.S. over safety concerns
Read the full article on Seeking Alpha
For further details see:
New York reports first locally acquired chikungunya case in U.S. since 2019
Valneva SE
NASDAQ: VALN
VALN Trading
1.47% G/L:
$10.7655 Last:
2,640 Volume:
$10.59 Open:
VALN Latest News
October 01, 2025 04:20:00 pm
Ongoing Valneva SE (VALN) Investigation: Protect Your Rights - Contact Levi & Korsinsky
VALN Stock Data
$798,793,290
73,508,485
N/A
10
N/A
Biotechnology & Life Sciences
Healthcare
FR
Lyon
